The product of HLA-A*30:02 allele, which is more frequent in Bahrain MS patients compared with in control subjects [25], is capable of binding the MBP peptide GYGGRASDY, which is released by proteasomes purified from cells exposed to IFNγ two orders of magnitude more efficiently than HEK293T proteasomes (Figure 5b). This evidence concerns the gene IFNG and myeloid sarcoma.